| Abstract | STUDY OBJECTIVES: Patients with COPD are at risk of experiencing a deterioration in arterial oxygen saturation (SaO2) during sleep, which is generally most pronounced during rapid eye movement (REM) sleep. Increased cholinergic tone has been suggested as a contributing factor to this decrease in SaO2. Therefore, we investigated whether 4-week treatment with ipratropium bromide inhalation solution 0.02% (qid) could improve sleep characteristics in COPD. DESIGN: Randomized, placebo-controlled, double-blind, two-arm parallel study of 4 weeks of treatment with ipratropium bromide solution or placebo. SETTING: Multicenter investigation. PATIENTS: Thirty-six patients with moderate-to-severe COPD (FEV1 < 65% of predicted). MEASUREMENTS AND RESULTS: Evaluation included polysomnographic, pulmonary function, and subjective quality of sleep (visual analog scale [VAS]) assessments. It was found that 4 week of treatment with ipratropium bromide solution in patients with COPD led to the following: (1) a significant (p = 0.05) improvement in mean nocturnal SaO2 with the more severe the nocturnal desaturation, the greater the improvement in SaO2; (2) significant (p = 0.03) improvement in perceived sleep quality (VAS: 5.5 +/- 0.5 after placebo; 7.2 +/- 0.5 after ipratropium); (3) a significant (p = 0.05) increase in REM sleep time (48.6 +/- 6.3 min after placebo; 66.5 +/- 6.4 min after ipratropium) with no effect on other sleep stages or total sleep time; and (4) a significant (p = 0.01) increase in pre-sleep FVC and flow rate at 50% of the vital capacity. CONCLUSIONS: These findings demonstrate that ipratropium bromide therapy can improve sleep SaO2 as well as sleep quality in patients with moderate-to-severe COPD. |
| Authors | R J Martin, B L Bartelson, P Smith, D W Hudgel, D Lewis, G Pohl, P Koker, J F Souhrada
(Affiliation: National Jewish Medical and Research Center, Denver, CO 80206, USA. martinr at njc.org)
|
| Journal | Chest
(Chest)
Vol. 115
Issue 5
Pg. 1338-45
(May 1999)
ISSN: 0012-3692 UNITED STATES |
| PMID | 10334150
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Bronchodilator Agents
- Cholinergic Antagonists
- Ipratropium
- Oxygen
|
| Topics |
- Adult
- Aged
- Bronchodilator Agents
(adverse effects, therapeutic use)
- Cholinergic Antagonists
(adverse effects, therapeutic use)
- Double-Blind Method
- Female
- Forced Expiratory Volume
- Humans
- Ipratropium
(adverse effects, therapeutic use)
- Lung Diseases, Obstructive
(drug therapy, physiopathology)
- Male
- Middle Aged
- Oxygen
(blood)
- Polysomnography
- Sleep Stages
- Vital Capacity
|
